# Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Source: https://onco.cc/trials/nct07421700/  
OnCo record `nct07421700` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PF-08634404 and Enfortumab vedotin in bladder & urothelial cancer, run by Pfizer, now recruiting.

## Summary

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer is a phase 1/2 interventional study registered as NCT07421700 by Pfizer, with 132 participants planned, started 2026-03-11 and due to reach its primary completion in 2027-12-06. Interventions recorded: PF-08634404 and Enfortumab Vedotin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07421700
- Phase: 1/2
- Setting: AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
- Sponsor: Pfizer
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT07421700: https://clinicaltrials.gov/study/NCT07421700

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [Astellas](https://onco.cc/companies/astellas/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct07421700.json